Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 31/5/2020
SIETES contiene 93020 citas

 
 
 1 a 20 de 52 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case–control study. Drug Saf 2019;42:septiembre. [Ref.ID 103178]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
McCormack J, Korownyk C. Effectiveness of antidepressants. BMJ 2018;360:k1073. [Ref.ID 102478]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cipriani A, Furukwa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. . Lancet 2018;391:7 de abril. [Ref.ID 102476]
4. Cita con resumen
Braithwaite R. Reboxetine has no antidepressant effect at all. BMJ 2015;351:h5842. [Ref.ID 99680]
5.Tiene citas relacionadas Cita con resumen
Godlee F. Withdraw approval for Tamiflu until NICE has full data. BMJ 2012;345:27. [Ref.ID 94247]
6. Cita con resumen
Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012:3 de agosto. [Ref.ID 92892]
7. Cita con resumen
Anónimo. H1 Reboxetine: benefit-risk balance reviewed. Drug Safety Update 2011;5:H1. [Ref.ID 90986]
8.Enlace a cita original
Laporte JR, Llop R, Bosch M. Avenços que canvien la pràctica clínica. Annals Med (Barc) 2011;94:S3-S10. [Ref.ID 90417]
9.Tiene citas relacionadas Cita con resumen
Krishnadas R. Reboxetine in depression. NICE guidance differs, so where next?. BMJ 2010;341:1064. [Ref.ID 89687]
10.Tiene citas relacionadas Cita con resumen
Turner EH. Reboxetine in depression. All the relevant data?. BMJ 2010;341:1064. [Ref.ID 89686]
11. Cita con resumen
Wieseler B, McGauran N, Kaiser T. Drug studies: a tale of hide and seek. BMJ 2010;341:809-10. [Ref.ID 89514]
12.Tiene citas relacionadas Cita con resumen
Godlee F, Loder E. Missing clinical trial data: setting the record straight. BMJ 2010;341:787-8. [Ref.ID 89206]
13.Tiene citas relacionadas Cita con resumen
Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kraiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:816. [Ref.ID 89205]
14.Tiene citas relacionadas Cita con resumen
Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:431-4. [Ref.ID 86544]
15.Tiene citas relacionadas Cita con resumen
Geddes JR, Barbui C, Cipriani A. Risk of suicidal behaviour in adults taking antidepressants. BMJ 2009;339:411-2. [Ref.ID 86541]
16. Cita con resumen
Anónimo. Milnacipran (Savella) for fibromyalgia. Med Lett Drugs Ther 2009;51:45-6. [Ref.ID 86242]
17. Cita con resumen
Stafford N. German agency asks Pfizer to disclose all reboxetine data. BMJ 2009;338:1522. [Ref.ID 86141]
18.Tiene citas relacionadas Cita con resumen
Parikh SV. Antidepressants are not all created equal. Lancet 2009;373:700-1. [Ref.ID 85087]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58. [Ref.ID 85086]
Seleccionar todas
 
 1 a 20 de 52 siguiente >>